Is Eyepoint Pharmaceuticals Stock a Good Investment?
Eyepoint Pharmaceuticals Investment Advice | EYPT |
- Examine Eyepoint Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Eyepoint Pharmaceuticals' leadership team and their track record. Good management can help Eyepoint Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Eyepoint Pharmaceuticals' business and its evolving consumer preferences.
- Compare Eyepoint Pharmaceuticals' performance and market position to its competitors. Analyze how Eyepoint Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Eyepoint Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Eyepoint Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Eyepoint Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Eyepoint Pharmaceuticals is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Eyepoint Pharmaceuticals Stock
Researching Eyepoint Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 94.0% of the company shares are held by institutions such as insurance companies. The book value of Eyepoint Pharmaceuticals was currently reported as 4.09. The company recorded a loss per share of 1.99. Eyepoint Pharmaceuticals last dividend was issued on the 9th of December 2020. The entity had 1:10 split on the 9th of December 2020.
To determine if Eyepoint Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Eyepoint Pharmaceuticals' research are outlined below:
| Eyepoint Pharmaceuticals generated a negative expected return over the last 90 days | |
| Eyepoint Pharmaceuticals has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 46.02 M. Net Loss for the year was (70.8 M) with loss before overhead, payroll, taxes, and interest of (64.48 M). | |
| Eyepoint Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Further weakness as EyePoint Pharmaceuticals drops 20 percent this week, taking one-year losses to 68 |
Eyepoint Pharmaceuticals Quarterly Cash And Short Term Investments |
|
Eyepoint Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Eyepoint Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eyepoint Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Eyepoint Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Eyepoint Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-02-07 | 2017-12-31 | -0.15 | -0.13 | 0.02 | 13 | ||
2024-08-07 | 2024-06-30 | -0.52 | -0.58 | -0.06 | 11 | ||
2022-03-03 | 2021-12-31 | -0.53 | -0.59 | -0.06 | 11 | ||
2021-08-04 | 2021-06-30 | -0.43 | -0.35 | 0.08 | 18 | ||
2012-11-08 | 2012-09-30 | -1 | -1.1 | -0.1 | 10 | ||
2023-05-03 | 2023-03-31 | -0.68 | -0.56 | 0.12 | 17 | ||
2024-05-08 | 2024-03-31 | -0.42 | -0.55 | -0.13 | 30 | ||
2020-05-06 | 2020-03-31 | -0.95 | -1.1 | -0.15 | 15 |
Eyepoint Pharmaceuticals Target Price Consensus
Eyepoint target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Eyepoint Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 12 | Strong Buy |
Most Eyepoint analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Eyepoint stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Eyepoint Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationEyepoint Pharmaceuticals Target Price Projection
Eyepoint Pharmaceuticals' current and average target prices are 8.53 and 33.42, respectively. The current price of Eyepoint Pharmaceuticals is the price at which Eyepoint Pharmaceuticals is currently trading. On the other hand, Eyepoint Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Eyepoint Pharmaceuticals Market Quote on 24th of January 2025
Target Price
Analyst Consensus On Eyepoint Pharmaceuticals Target Price
Eyepoint Pharmaceuticals Analyst Ratings
Eyepoint Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Eyepoint Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Eyepoint Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Eyepoint Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Know Eyepoint Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eyepoint Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eyepoint Pharmaceuticals backward and forwards among themselves. Eyepoint Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Eyepoint Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Patient Square Capital | 2024-09-30 | 1.4 M | T. Rowe Price Investment Management,inc. | 2024-09-30 | 1.3 M | State Street Corp | 2024-09-30 | 1.2 M | Goldman Sachs Group Inc | 2024-09-30 | 1.2 M | Geode Capital Management, Llc | 2024-09-30 | 1.2 M | Octagon Capital Advisors Lp | 2024-09-30 | 1.1 M | 5am Venture Management, Llc | 2024-09-30 | 1.1 M | Perceptive Advisors Llc | 2024-09-30 | 1 M | Tcg Crossover Management, Llc | 2024-09-30 | 922.3 K | Cormorant Asset Management, Llc | 2024-09-30 | 8.3 M | Suvretta Capital Management, Llc | 2024-09-30 | 5.2 M |
Eyepoint Pharmaceuticals' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 601.97 M.Market Cap |
|
Eyepoint Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.18) | (0.19) | |
| Return On Capital Employed | (0.30) | (0.31) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.31) | (0.32) |
Determining Eyepoint Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Eyepoint Pharmaceuticals is a good buy. For example, gross profit margin measures Eyepoint Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Eyepoint Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Eyepoint Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Eyepoint Pharmaceuticals. Check Eyepoint Pharmaceuticals' Beneish M Score to see the likelihood of Eyepoint Pharmaceuticals' management manipulating its earnings.
Evaluate Eyepoint Pharmaceuticals' management efficiency
Eyepoint Pharmaceuticals has return on total asset (ROA) of (0.3139) % which means that it has lost $0.3139 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7468) %, meaning that it created substantial loss on money invested by shareholders. Eyepoint Pharmaceuticals' management efficiency ratios could be used to measure how well Eyepoint Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.19 in 2025. Return On Capital Employed is likely to drop to -0.31 in 2025. At this time, Eyepoint Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 428.9 M in 2025, whereas Non Current Liabilities Total is likely to drop slightly above 17.4 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.87 | 7.48 | |
| Tangible Book Value Per Share | 6.16 | 6.47 | |
| Enterprise Value Over EBITDA | (7.82) | (8.21) | |
| Price Book Value Ratio | 3.78 | 3.59 | |
| Enterprise Value Multiple | (7.82) | (8.21) | |
| Price Fair Value | 3.78 | 3.59 | |
| Enterprise Value | 70 M | 66.5 M |
Effective leadership at Eyepoint Pharmaceuticals drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 1.517 |
Basic technical analysis of Eyepoint Stock
As of the 24th of January, Eyepoint Pharmaceuticals shows the Variance of 35.89, mean deviation of 4.34, and Standard Deviation of 5.99. Eyepoint Pharmaceuticals technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Eyepoint Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eyepoint Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eyepoint Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eyepoint Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Eyepoint Pharmaceuticals' Outstanding Corporate Bonds
Eyepoint Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Eyepoint Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Eyepoint bonds can be classified according to their maturity, which is the date when Eyepoint Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| EXXON MOBIL P Corp BondUS30231GAN25 | View | |
| EXXON MOBIL P Corp BondUS30231GAF90 | View | |
| EXXON MOBIL P Corp BondUS30231GBK76 | View | |
| EXXON MOBIL P Corp BondUS30231GBN16 | View | |
| EXXON MOBIL P Corp BondUS30231GBM33 | View | |
| EXXON MOBIL P Corp BondUS30231GBG64 | View | |
| EXXON MOBIL P Corp BondUS30231GBF81 | View | |
| EXXON MOBIL P Corp BondUS30231GBJ04 | View |
Understand Eyepoint Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Eyepoint Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 1.29 | |||
| Mean Deviation | 4.34 | |||
| Coefficient Of Variation | (2,709) | |||
| Standard Deviation | 5.99 | |||
| Variance | 35.89 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.22) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | 1.28 | |||
| Maximum Drawdown | 40.16 | |||
| Value At Risk | (7.35) | |||
| Potential Upside | 7.34 | |||
| Skewness | 1.62 | |||
| Kurtosis | 6.18 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 1.29 | |||
| Mean Deviation | 4.34 | |||
| Coefficient Of Variation | (2,709) | |||
| Standard Deviation | 5.99 | |||
| Variance | 35.89 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.22) | |||
| Total Risk Alpha | (0.50) | |||
| Treynor Ratio | 1.28 | |||
| Maximum Drawdown | 40.16 | |||
| Value At Risk | (7.35) | |||
| Potential Upside | 7.34 | |||
| Skewness | 1.62 | |||
| Kurtosis | 6.18 |
Consider Eyepoint Pharmaceuticals' intraday indicators
Eyepoint Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Eyepoint Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 16219.68 | |||
| Daily Balance Of Power | (0.45) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 8.59 | |||
| Day Typical Price | 8.57 | |||
| Price Action Indicator | (0.16) | |||
| Period Momentum Indicator | (0.19) | |||
| Relative Strength Index | 60.53 |
Eyepoint Pharmaceuticals Corporate Filings
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 7th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 6th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Eyepoint Stock media impact
Far too much social signal, news, headlines, and media speculation about Eyepoint Pharmaceuticals that are available to investors today. That information is available publicly through Eyepoint media outlets and privately through word of mouth or via Eyepoint internal channels. However, regardless of the origin, that massive amount of Eyepoint data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Eyepoint Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Eyepoint Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Eyepoint Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Eyepoint Pharmaceuticals alpha.
Eyepoint Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Eyepoint Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Eyepoint Pharmaceuticals Maximum Pain Price Across April 17th 2025 Option Contracts
Eyepoint Pharmaceuticals' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Eyepoint Pharmaceuticals close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Eyepoint Pharmaceuticals' options.
Eyepoint Pharmaceuticals Corporate Management
| David Jones | Senior Officer | Profile | |
| Jay MD | Chief Officer | Profile | |
| Michael Pine | Chief Officer | Profile | |
| Ramiro MD | Chief Officer | Profile | |
| Jennifer Leonard | Chief IT | Profile |
Additional Tools for Eyepoint Stock Analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.